Business Wire

SAMSUNG-BIOEPIS

9.10.2019 08:02:12 CEST | Business Wire | Press release

Share
Samsung Bioepis Presents Real-world Data of BENEPALI™ (etanercept) in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

Samsung Bioepis Co., Ltd. today announced real-world data of BENEPALI™ in patients with moderate to severe psoriasis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). The results will be presented at the 2019 European Academy of Dermatology and Venereology (EADV) Congress in Madrid, Spain.1

BADBIR is a UK and Ireland observational study that assesses the long-term safety of biologic treatments for psoriasis, in which Samsung Bioepis participated since May 2016. The study included BADBIR-registered patients treated with BENEPALI™ from January 01, 2016 to September 01, 2018. Among 269 patients who received BENEPALI™, clinical data of 189 patients were available, and were included in the analysis.

At baseline enrollment, the mean disease duration was 22.6 years and the mean Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores were 11.6 and 13.1, respectively. The median treatment period was 14.1 months and the discontinuation rate was 26.3%. Of the 48 patients who had their PASI score available both at baseline and at six months, disease activity of 20 patients with baseline PASI < 10 (mean PASI 3.2) did not increase after six months (mean PASI 3.2). Disease activity of 28 patients with baseline PASI ≥ 10 (mean PASI 15.7) was reduced after six months (mean PASI 5.0).

“Results from this study show that BENEPALI was effective when used by patients in the real-life setting,” said Seongwon Han, MD, Vice President and Lead of Medical Team, Samsung Bioepis. “We hope the growing wealth of real-world data on BENEPALI will help physicians make informed decisions when treating patients with biosimilars.”

The results will be presented during an Oral Free Communication session scheduled at 15:40-15:50 on October 10, 2019 in N109-110. Samsung Bioepis and Biogen are also jointly hosting an Industry Hub Session titled “Shedding new light on the role of anti-TNFs in psoriasis” which will take place between 14:00-14:45 on October 10, 2019 in Room A9.1, IFEMA Ferida de Madrid, Spain. Topics include “Anti-TNFs in psoriasis: Will the use of more affordable options enhance current treatment algorithms?” and “Anti-TNF biosimilars: Real world insights and data.”

Samsung Bioepis and Biogen were the first to launch biosimilars of the three most prescribed anti-TNF therapies for immunological diseases across Europe: etanercept, infliximab and adalimumab.

About BENEPALITM (etanercept)

BENEPALI™ (etanercept), a biosimilar referencing ENBREL®2 , was approved by the European Commission (EC) in January 2016 for the treatment of adults with moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis), and plaque psoriasis. BENEPALI™ is currently available in 25 countries in Europe and is the most prescribed etanercept across France, Germany, Italy, Spain, and the United Kingdom combined.3

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .

1. Egeberg et al., Real World Data of SB4 (Etanercept Biosimilar) in Patients with Psoriasis from the British Association of Dermatologists Biologic Interventions Register (BADBIR). EADV 2019, Madrid, Spain
2. ENBREL® is a registered trademark of Amgen/Pfizer.
3. Data on File: IQVIA, GERS, Insight Health ODV

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Grid Dynamics Appoints Industry Veteran Nikita Ivanov as Head of AI26.8.2026 22:05:00 CEST | Press release

Key Takeaways: As Vice President, Head of AI, Nikita Ivanov leads the strategic direction of Grid Dynamics' AI portfolio, including its GAIN platforms, and helps clients convert AI pilots into measurable value in production. Ivanov has over two decades of founding and scaling technology companies as an entrepreneur and technologist, adding commercial and operational depth to Grid Dynamics' executive team. Focused on moving Fortune 1000 clients to AI-native software delivery, Ivanov is advancing Grid Dynamics' AI-SDLC tools that give enterprises a faster, more reliable path to building and running AI systems. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, is advancing its AI strategy under the leadership of Nikita Ivanov, Vice President, Head of AI. Ivanov is responsible for leading the transition efforts of Grid Dynamics’ clients toward an AI-native software delivery model, and he oversees all elements of Grid Dy

Arc'teryx Introduces System 0™, a New Framework for the Future of Product Design and Circularity26.8.2026 15:00:00 CEST | Press release

Sperro SV, a multisport mountain-grade hardshell built with circular design principles, available September 4, 2026 Arc'teryx Equipment, the global design company specializing in technical high-performance apparel and equipment, today introduced System 0™, a new framework that reimagines how products can be designed, manufactured, used, repaired, and ultimately regenerated. System 0 represents the next evolution for sustainability in the outdoor industry, as it embeds circular thinking across an entire product lifecycle while maintaining the uncompromising performance standards that define the Arc’teryx brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826686539/en/ Arc’teryx athlete, Craig Murray, wearing the Sperro SV, a multisport mountain-grade hardshell built with circular design principles, available September 4, 2026. The first product being introduced as part of the System 0 platform is the Sperro SV jacket, a

Xsolla Announces Five-Year Partnership With the Global Esports Federation26.8.2026 15:00:00 CEST | Press release

Partnership Represents a Structural Shift in Esports, Placing Xsolla's Infrastructure Behind GEF’s Entire Ecosystem, Spanning Commerce, Payments, Wallet, Loyalty, and Distribution Across Global Esports Games, Global Esports Tour, and 180+ Member Federations Xsolla, a global commerce company, today announced a landmark five-year strategic partnership with the Global Esports Federation (GEF), the world-convening body for esports. As GEF's exclusive partner for commerce, payments, wallet, loyalty, and distribution, Xsolla will power the entire GEF ecosystem, including the flagship Global Esports Games, pro-series Global Esports Tour, global GEFcon, and 180+ Member Federations across five continents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826948844/en/ Graphic: Xsolla The announcement comes as GEF marks 100 days to go to the Los Angeles 2026 Global Esports Games (GEGLA26), adding further momentum to the road to Los An

NABEP Appoints Sara Chouraqui as General Counsel26.8.2026 15:00:00 CEST | Press release

Company expands legal team as it prepares for significant growth North American Blue Energy Partners (NABEP) has appointed Sara Chouraqui as General Counsel, with Elizabeth Collery and Victoria Jacobson each joining as Deputy General Counsel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826168543/en/ Sara Chouraqui joins NABEP as its General Counsel, bringing decades of legal expertise. These additions significantly strengthen NABEP’s senior leadership team and legal expertise as the company improves its operations, increases production and develops new strategic and commercial partnerships. As General Counsel, Chouraqui will lead NABEP’s global legal function and advise the company’s leadership on its legal, regulatory and corporate priorities, including major transactions and partnerships, governance, compliance and the management of legal and regulatory risk across the company’s operations. Her experience navigating

Grafana Labs Crosses 10,000-Customer Milestone as AI Adoption Accelerates Growth Across the Platform26.8.2026 15:00:00 CEST | Press release

Grafana Labs was recently recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Observability Platforms for the third consecutive year, launched six AI-native products during its inaugural AI Week, and surpassed $600M in Annual Recurring Revenue. Grafana Labs, the company behind the open observability cloud, today announced it has crossed 10,000 customers worldwide and surpassed $600 million in annual recurring revenue, as organizations standardize on open observability for the AI era. Teams need AI to help them understand their own systems faster, especially as complexity and overhead remain the top observability concern cited in Grafana Labs' 2026 Observability Survey – a need reflected by the adoption of Grafana Assistant, Grafana Cloud's context-aware AI agent for exploring and troubleshooting observability data, now used by more than 18,000 organizations. Teams also need observability purpose-built for AI systems themselves: When teams move AI into production, models dri

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye